REMS for Clozapine: What Changed in 2025 for ANC Monitoring and Patient Safety
As of February 2025, the FDA removed the mandatory REMS program for clozapine, ending strict ANC monitoring requirements. ANC blood tests are still recommended, but no longer need to be reported to a federal system. This change improves access to the most effective treatment for treatment-resistant schizophrenia.
Continue reading...